ML
Therapeutic Areas
bioAffinity Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CyPath® Lung | Early-stage lung cancer diagnosis | Commercial |
| Platform Expansion - Diagnostics | Other cancers (unspecified) | Research & Development |
| Therapeutic Discovery | Targeted cancer treatment | Research & Development |
Leadership Team at bioAffinity Technologies
MZ
Maria Zannes
President and Chief Executive Officer
JA
Julie Anne Overton
Director of Communications
WB
W.E. Bauta
Scientist/Researcher (co-author)
MG
M.H. Grayson
Scientist/Researcher (co-author)
RT
R. Titone
Scientist/Researcher (co-author)
JR
J. Rebeles
Scientist/Researcher (co-author)
VR
V.I. Rebel
Scientist/Researcher (co-author)
XR
X.T. Reveles
Scientist/Researcher (co-author)
LB
L.H. Bederka
Scientist/Researcher (co-author)
PA
P.R. Araujo
Scientist/Researcher (co-author)